The company has developed a drug delivery and discovery platform that enables the creation of highly targeted, small molecule medicines with unmatched selectivity, potency, and efficacy. Terremoto's platform allows for the delivery of medicines with optimized clinical profiles, superior therapeutic benefits, and the ability to cure devastating diseases. The company is focused on developing both best-in-class therapies against known drug targets and first-in-class medicines against previously undruggable targets, with the goal of delivering superior therapeutic benefits. Terremoto is supported by leading investors OrbiMed and Third Rock Ventures.